291 related articles for article (PubMed ID: 30874910)
1. Current Update on the Molecular Biology of Cutaneous Sarcoma: Dermatofibrosarcoma Protuberans.
Iwasaki T; Yamamoto H; Oda Y
Curr Treat Options Oncol; 2019 Mar; 20(4):29. PubMed ID: 30874910
[TBL] [Abstract][Full Text] [Related]
2. Dermatofibrosarcoma Protuberans.
Reha J; Katz SC
Surg Clin North Am; 2016 Oct; 96(5):1031-46. PubMed ID: 27542641
[TBL] [Abstract][Full Text] [Related]
3. Dermatofibrosarcoma protuberans: pathology, genetics, and potential therapeutic strategies.
Thway K; Noujaim J; Jones RL; Fisher C
Ann Diagn Pathol; 2016 Dec; 25():64-71. PubMed ID: 27806849
[TBL] [Abstract][Full Text] [Related]
4. Dermatofibrosarcoma Protuberans.
Acosta AE; Vélez CS
Curr Treat Options Oncol; 2017 Aug; 18(9):56. PubMed ID: 28795284
[TBL] [Abstract][Full Text] [Related]
5. Transformed dermatofibrosarcoma protuberans: real time polymerase chain reaction detection of COL1A1-PDGFB fusion transcripts in sarcomatous areas.
Szollosi Z; Scholtz B; Egervari K; Nemes Z
J Clin Pathol; 2007 Feb; 60(2):190-4. PubMed ID: 16731589
[TBL] [Abstract][Full Text] [Related]
6. [Dermatofibrosarcoma protuberans].
Ugurel S
Hautarzt; 2008 Nov; 59(11):933-9; quiz 940. PubMed ID: 18936902
[TBL] [Abstract][Full Text] [Related]
7. Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management.
Llombart B; Serra-Guillén C; Monteagudo C; López Guerrero JA; Sanmartín O
Semin Diagn Pathol; 2013 Feb; 30(1):13-28. PubMed ID: 23327727
[TBL] [Abstract][Full Text] [Related]
8. Target therapy of unresectable or metastatic dermatofibrosarcoma protuberans with imatinib mesylate: an analysis on 22 Chinese patients.
Wang C; Luo Z; Chen J; Zheng B; Zhang R; Chen Y; Shi Y
Medicine (Baltimore); 2015 May; 94(17):e773. PubMed ID: 25929918
[TBL] [Abstract][Full Text] [Related]
9. Plaque-like CD34-positive dermal fibroma ("medallion-like dermal dendrocyte hamartoma"): clinicopathologic, immunohistochemical, and molecular analysis of 5 cases emphasizing its distinction from superficial, plaque-like dermatofibrosarcoma protuberans.
Kutzner H; Mentzel T; Palmedo G; Hantschke M; Rütten A; Paredes BE; Schärer L; Guillen CS; Requena L
Am J Surg Pathol; 2010 Feb; 34(2):190-201. PubMed ID: 20061935
[TBL] [Abstract][Full Text] [Related]
10. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans.
Maki RG; Awan RA; Dixon RH; Jhanwar S; Antonescu CR
Int J Cancer; 2002 Aug; 100(6):623-6. PubMed ID: 12209598
[TBL] [Abstract][Full Text] [Related]
11. Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation.
Rutkowski P; Klimczak A; Ługowska I; Jagielska B; Wągrodzki M; Dębiec-Rychter M; Pieńkowska-Grela B; Świtaj T
Eur J Surg Oncol; 2017 Jun; 43(6):1134-1141. PubMed ID: 28365129
[TBL] [Abstract][Full Text] [Related]
12. Dermatofibrosarcoma protuberans COL1A1-PDGFB fusion is identified in virtually all dermatofibrosarcoma protuberans cases when investigated by newly developed multiplex reverse transcription polymerase chain reaction and fluorescence in situ hybridization assays.
Patel KU; Szabo SS; Hernandez VS; Prieto VG; Abruzzo LV; Lazar AJ; López-Terrada D
Hum Pathol; 2008 Feb; 39(2):184-93. PubMed ID: 17950782
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical characterization of dermatofibrosarcoma protuberans with practical applications for diagnosis and treatment.
Haycox CL; Odland PB; Olbricht SM; Piepkorn M
J Am Acad Dermatol; 1997 Sep; 37(3 Pt 1):438-44. PubMed ID: 9308560
[TBL] [Abstract][Full Text] [Related]
14. Current treatment options for dermatofibrosarcoma protuberans.
Rutkowski P; Debiec-Rychter M
Expert Rev Anticancer Ther; 2015; 15(8):901-9. PubMed ID: 26027711
[TBL] [Abstract][Full Text] [Related]
15. Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection.
Rutkowski P; Dębiec-Rychter M; Nowecki Z; Michej W; Symonides M; Ptaszynski K; Ruka W
J Eur Acad Dermatol Venereol; 2011 Mar; 25(3):264-70. PubMed ID: 20569296
[TBL] [Abstract][Full Text] [Related]
16. PDGFB rearrangement in dermatofibrosarcoma protuberans: correlation with clinicopathologic characteristics and clinical implications.
Ha SY; Lee SE; Kwon MJ; Kim YJ; Lee EH; Seo J; Jang KT; Lee J; Choi YL
Hum Pathol; 2013 Jul; 44(7):1300-9. PubMed ID: 23347652
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and treatment of dermatofibrosarcoma protuberans. European consensus-based interdisciplinary guideline.
Saiag P; Grob JJ; Lebbe C; Malvehy J; del Marmol V; Pehamberger H; Peris K; Stratigos A; Middelton M; Basholt L; Testori A; Garbe C
Eur J Cancer; 2015 Nov; 51(17):2604-8. PubMed ID: 26189684
[TBL] [Abstract][Full Text] [Related]
18. Dermatofibrosarcoma protuberans in children: an update on the diagnosis and treatment.
Kornik RI; Muchard LK; Teng JM
Pediatr Dermatol; 2012; 29(6):707-13. PubMed ID: 22780227
[TBL] [Abstract][Full Text] [Related]
19. Application of COL1A1-PDGFB fusion gene detection by fluorescence in situ hybridization in biopsy tissue of dermatofibrosarcoma protuberans.
Zhang Z; Chen H; Chen M; He X; Wang Y; Zhang H
J Dermatol; 2017 Jul; 44(7):798-802. PubMed ID: 28150334
[TBL] [Abstract][Full Text] [Related]
20. Remission with Imatinib mesylate treatment in a patient with initially unresectable dermatofibrosarcoma protuberans--a case report.
Lemm D; Muegge LO; Hoeffken K; Aklan T; Mentzel T; Thorwarth M; Schultze-Mosgau S
Oral Maxillofac Surg; 2008 Dec; 12(4):209-13. PubMed ID: 18751744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]